Direct technetium-99m labeling of anti-hepatoma monoclonal antibody fragment: a radioimmunoconjugate for hepatocellular carcinoma imaging

Abstract

Direct technetium-99m labeling of anti-hepatoma monoclonal antibody fragment: a radioimmunoconjugate for hepatocellular carcinoma imaging

Hui Jie Bian1, Zhi Nan Chen1 and Jing Lan Deng2

1Cell Engineering Research Center, Basic Medical Department, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
2Department of Clinical Nuclear Medicine, Xijing Hospital, Xi’an 710033, Shaanxi Province, China

World J Gastroenterol  2000;June6(3):348-352

Supported by National Natural Science Foundation of China, No.39700175

 

Subject headings: antibody, monoclonal; antibody fragments; technetium-99m; hepatocellular carcinoma; liver neoplasms; radioimmunoimaging

 

Abstract
AIM: To directly radiolabel an anti-hepatoma mAb fragment HAb18 F(ab’)2 with 99mTc by stannous-reduced method, and assess the stability, biodistribution and radioimmun oimaging (R).

METHODS: Immunoreactive fraction was determined according to Lin dmo’s method. Ellman’s reagent was used to determine the number of thiols in the reduced F(ab’)2. Labeling efficiency and homogeneity were measured by paper chromatography, sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and autora diography. Challenge assay involved the incubation of aliquots of labeled antibo dy in ethylenediaminetetraacetate (EDTA) and L-cysteine (L-cys) solutions with different molar ratio at 37
for 1h, respectively. Investigations in vivo utilized nude mice bearing human hepatocellular carcinoma (HHCC) xenografts with gamma camera imaging and tissue biodistribution studies at regular intervals.

RESULTS: The labeling procedure was finished within 1.5h compared with the “pretinning” method which would take at least 21h. In vitro studies demonstrated that the radiolabeled mAb fragment was homogen eous and retained its immunoreactivity. Challenge studies indicated that 99mTc-labeled HAb18 F(ab’)2 in EDTA is more stable than in L-cys. Imaging and biodistribution showed a significant tumor uptake at 24h post-injection of 99mTc-labeled HAb18 F(ab’)2. The blood, kidney, liver and tumor uptakes at 24h were 0.56±0.09, 56.45±11.36, 1.43±0.27 and 6.57±3.01 (%ID/g)
respectively.

CONCLUSION: 99mTc-HAb18 F(ab’)2 conjugate prepare d by this direct method appears to be an effective way to detect hepatoma in nude mice model.
 

 

 


Introduction

The introduction of mAbs as targeting devices in nuclear medicine is well develo ped and many different antibodies which labeled with a variety of isotopes have been reported in cancer diagnosis. It seemed that 99mTc is the most popular radionuclide for nuclear medicine imaging because of its favorable physi cal characteristics, low cost, and ready availability. 99mTc labeled mAb fragments should be superior to other big molecule radioimmunoconjugates for u se in tumor R. A number of methods have been proposed for 99mTc labe ling proteins, and mAbs in particular. In general, these methodologies can be d ivided into two categories: indirect and direct methods[1]. In indirect method the protein was modified with a technetium binding ligand and then reacte d with a technetium complex. Several bifunctional chelating agents have been syn thesized and used, such as diethylenetriaminepenta acetic acid (DTPA)[2] , diamide dimercaptide N2S2 ligands, and hydrazino nicotinamide analog [3]. Although it is said that the indirect method can lead to loss of immuno reactivity. Joiris et al. have tested that the derivatization of antibody or fragment by iminothiolane does not split the protein and keeps the immunoreact ivity[4]. By direct method, 99mTc metal ion binds directly to endogenous donor groups on the antibody. The method is simple to perform and co mpatible with practical clinical use. However, direct labeling of mAbs with 99mTc was reported to be unstable due to non-specific binding (low and high-affinity)[5,6]but some reports suggest an improved labeling of proteins with 99mTc. In the Schwarz and Steinstrasser procedure, as modified by Mather and Ellison[7], disulide bridges in the mAb are reduc ed with 2-mercaptoethanol (2-ME). After purification, the resulting reduced an tibody can be stored frozen until required for use. Labeling is accomplished by addition of stannous ion from a bone- scanning kit and pertechnetate. In addit ion to using regular reducing agents, such as 2-ME, stannous ions[8]b orohydride[9], ascorbic acid[10], dithionite[11], or gl utathione[12]to generate sulphydryl groups, other peculiar approaches also appeared recently. Direct 99mTc labeling of mAbs were finis hed by reduction of antibodies using photoactivation and insoluble macromolecula r Sn() complex[13,14]. With the development of direct method, there ha ve been a few reports of successful use of this technique in colorectal, breast, and ovarian cancer imaging[15-17].
     
In this report, we describe a direct method for radiolabeling anti-hepatoma mon oclonal antibody fragment HAb 18F (ab’)2 with 99mTc. The stability and homogeneity of 99mc-HAb18 F(ab’)2 were evaluated. The biodis tribution and tumor localization in nude mice bearing a HHCC xenograft were studied.

Materials and Methods

Monoclonal antibody
The mAb HAb18 is of murine IgG1 isotype and was developed by our laboratory[18]. F(ab’)2 fragment of HAb18 was generated by papain digestion with a molecular weight of
96000 dalton[19].

Tumors
Hepatocellular carcinoma grown in Balb/c mice was used as a prototype tumo r model. Approximately 107 HHCC cells obtained from Shanghai Cell Institute of Chinese Academy of Sciences were implanted in the left thigh of the animals and the tumors were allowed to grow for 8-10 days to approximately 1cm in diameter.

Antibody reduction
The antibody concentrated to 8g/L in neutral PBS was reduced by reaction with a molar excess of stannous/glucoheptonate (Sn/GH) ranging from 10
1 to 501 (Sn/GH: MAb) at 37 for 15min-30min. The Sn/GH with a mass ratio of 1100 was dissolved in 50mM acetate-buffered saline (ABS), pH 5.3 purged with nitrogen. The reduced antibody was isolated from reductant t hro ugh a PD-10 column (Pharmacia) equilibrated with 0.05mol/L ABS. The number of resulting free sulphydryl groups was assayed with Ellman’s reagent 55’dithio-bis (2-nitrobenzoic acid), (DTNB, Sigma Chemical Co., USA) [20]. One hundred μL of sample was mixed with 20μL of 0.01mol/L-DTNB and diluted to 3mL with 0.05mol/L Tris-HCl buffer pH 8.4. The mixture was incubated at room te mperature for 15min and coloration measured with an UV/VIS spectrophotome ter at 412nm. The number of thiols was obtained by comparison with a seri es of L-cysteine (L-cys) standards ranging from 0.312mg/L to 10mg/L.
      The integrity of the reduced F(ab’)2 was determined by non-reduced SDS-PAGE with 100g/L gel using Vertical Gel Electrophoresis System (Bio-Rad). The gel was stained with Coomassie brilliant blue R250.Control experiments were run using unreduced mAb F(ab’)2.

Radiolabeling
For labeling, 160μg of reduced HAb18 F(ab’)2 was mixed with a 10μL-20μL of diluted Sn/GH solution (0.2g/L), and pertechnetium solution (0.2mL , 74MBq), (Chinese Academy of Atomic Energy) was injected into the mixture . The Sn/GH solution was freshly prepared each time by dissolving 100mg GH and 1mg SnCl2·2H2O in 5mL of saline purged with nitrogen. The reaction mixture was incubated for 0.5h-1h at 37
before it was analyzed by Whatman 3MM paper chromatography which was then developed in acetone or 100g/L trichloroacetic acid (TCA). R-f values for acetone are: mAb 0.0, 99mTc-GH 0.0, and 99mTcO4-0.9-1.0. R-f values for 100g/L TCA are: mAb 0.0, 99mTcGH 0, and 99mTcO4- 0.7. Labeled mAb was differentiated from 99mTc colloid by the method of Thrall et al[21]. The same strips impregnated with 10g/L-20g/L human serum albumin before development with 521, waterethanol5N NH4OH. Colloid remained on the bottom of the strip while mAb-bound isotope migrated with the solvent front.
      The integrity of the labeled F(ab’)2 was assayed using the same non-reduced SDS-PAGE as described above. The gel was autoradiograghied on x-ray film before stained with Coomassie brilliant blue R250.

Immunoreactivity assessment
The in vitro immunoreactivity of the radiolabeled HAb18 F(ab’)2 was evalu ated by a live cell assay[22]. Briefly, HHCC cells 5×109/L were centrifuged (1000r/min) for 5min and washed twice with 1% bovine serum albumin (BSA) in PBS, then 5 serial 1
2 dilutions were made in 10g/L BSA in Eppendorf tubes precoated with BSA. Radiolabeled HAb18 F(ab’)2 at a concentration of 40ng/mL in 10g/L BSA was added using a volume equal to half the volume of cell suspension. The total volume of cell-binding assay solution was 0.3mL. After incubation for 2h at 37, the total as well as the cell-bound radioactivity were counted in a gamma counter.

In Vitro stability studies
The stability was analyzed by using two different challenging agents, EDTA and L-cys. An aliquot of 50μL 99mTc-HAb 18 F(ab’)2 solution was incubated with EDTA or L-cys at 37
for 1h. The molar ratio of mAb to challenging agent was at a maximum of 100001. Dissociation ratio was analyzed on paper chromatography.

Biodistribution and imaging
Balb/c mice bearing HHCC were divided into three groups. Each group consisted of three animals and each animal received approximately 15μ g antibody with about 7.4MBq through a lateral tail vein. At time i ntervals of 4, 10 and 24h postinjection, three groups of mice were killed , and imaged on a SPECT (Starcam 3000, UK). Data were collected 100000 co unts per image and peak energy settings at the 140ke V (20%) window for 99mTc. The blood and other organs of interest were collected. Tissues were w ashed, blotted, weighed and counted in a gamma counter. For each mouse, data are expressed as percent of injected dose per gram of tissue (%ID/g) after physical decay corrected.

Results

Figure 1 represents the calibration curve for the determination of sulphydryl groups using L-cys standards over a range of 0.312 to 10mg/L, by plotting optical density at 412nm versus L-cys standard concentrations after subtraction of the background due to Ellman’s reagent. Linear regression was used and correlation coefficient 0.999 was obtained. Table 1 shows the influence of the reduction conditions on the number of free sulphydryl groups detected by this thiol assay. As expected, increasing the molar ratio of Sn/GH to antibody in the reaction mixture does increase the number of apparent -SH groups per antibody, and increase the labeling efficiency correspondingly, which results in the labeling efficiency at a maximum of 84.2%. The free 99mTcO4- and colloid amounts determined by Whatman 3MM paper using different developing systems were also showed in Table 1. In control expe ri ments, labeling efficiency was 2% when unreduced HAb18 F(ab’)2 was used. SD S-PAGE by both staining and autoradiography showed that the radioactivity co-m igrated with the proteins and that there were almost no protein fragments prese nt within the 601 of molar ratio of Sn/GH to mAb (Figure 2). However , another SDS-PAGE in Figure 3 illustrates that fragmentation occurred during t he reduction procedure when the molar ratio of Sn/GH to mAb was at 500 1.
      As shown in Figure 4, the immunoreactive fraction, 0.84 was determined by plott ing the inverse of the bound fraction compared with the inverse of the cell conc entration, which is based on the assumption that the total antigen concentration (cell concentration) is a good enough approximation for the free antig en concentration.
      Challenging with EDTA did not remove 99mTc from the labeling conjugat e remarkably, while L-cys at a molar ratio of 6251 remove approximately one-tenth of the label (Figure 5).
      Biodistribution of radioactivity in blood and excised tissues are displayed in Table 2. The preparation localized at the tumors was more than at any organ examined at both 10h and 24h after injection, except the kidneys. Th e lower radioactivity in blood at 24h suggested fast blood clearance. The imaging results in Figure 6 showed significant tumor uptake at 24h post-i njection.

 


Discussion

Great efforts have been made to develop a method that can be used for the direct labeling of mAbs with 99mTc[16]. Earlier studies involved the incubation of mAbs with stannous phthalate tartrate solution for up to 21h at room temperature, which was named “pretinning” method. Clinical success with this method has been claimed by the author[23].
     
One aim of our study was to further evaluate the role of stannous as a reducing agent in the direct labeling of mAb F(ab’) 2 with 99mTc. The difference between the “pretinning” method and this method is that we use GH instead of phthalate-tartrate as transfer ligand and stabilizer to avoid Sn or Tc-c olloid formation. To do this, we investigated the effect of the quantity of Sn/ GH on the labeling time and efficiency. When the molar ratio of Sn/GH to mA b F(ab’)2 was constant, we found that there was no obvious difference on the number of-SH between the reduction time of 20min and 30min or even longer[ 24]. The whole labeling process can be accomplished within 1.5h. Hnatowich et al. reported that labeling efficiency in the case of the stannous ion-reduced a ntibodies was generally in excess of 70%[12], however, in our method mol ar ratio of Sn/GH to mAb was an important parameter to obtain good labeling re sults, and molar ratio of 401 or higher were needed to get labeling effici ency of more than 80% (Table 1). The low percentage of free 99mTcO4 and radiocolloid in each sample implied that pH 5.3 and GH are the opti mal pH value and transfer ligand. Under this condition, the labeled mAb HAb18 F( ab’)2 keeps its immunoreactivity. Autoradiography of SDS-PAGE had only one m igration of component identical to that of native HAb18 F(ab’)2 determination by staini ng with Coomassie brilliant blue R250 (Figure 2), which demonstrated that S n/GH reduction is mild and does not destroy interchain bridges in mAbs. Labeli ng efficiency of 2% in control experiments using unreduced HAb18 F(ab’)2 indicated that there was no exchange with the low affinity sites and also demonstrated tha t reduction of disulfides is a necessary initial step in 99mc direct labeling of antibodies. The bond between SH and Tc is stronger than that of N -Tc or O-Tc which was verified by the challenge assay of 99mTc-HAb18 F(ab’)2 in the presence of EDTA. We found that EDTA even at a molar rat io of 100001 failed to remove a significant amount of 99mTc, this is in agreement with the results of Rhodes et al[8]. But L-cys at 6251 remove one-tenth of the label (Figure 5). Despite such insta bility of the label, there was no in vivo evidence of release of pertechneta te due to no thyroid imaging observed in the whole imaging process (Figure 7) . Tumor localization of 99mTc-HAb18 F(ab’)2 was successfully dem onstrated in a human tumor/nude mouse xenograft model. Biodistribution and ima ging results showed the highest tumor uptake at 24h post-injection. Where as kidney levels were foun d to be higher in the whole process. Accumulation of radioactivity in the kidney may be the result of retention of this metallic radionuclide by the kidney pro ximal tubule[25], the possible release of 99mTc-labeled cysteine and gluta thione[26]stemming from the radioimmunoconjugate catabolism, and the r elative amount of 99mTc-GH. A technique has been used in patients to block renal tubule uptake of 99mTc-anti-CEA Fab’ fragments by amin o acid infusion[27].
     
In conclusion, a radioimmunoimaging conjugate for hepatoma detection was prepare d by direct labeling mAb HAb18 F(ab’)2-with 99mTc using stannous/g lucoheptonate as reducing agent. Although the labeling efficiency is not satisf actory to some degree, it has several advantapes: simple, easy and quick, besid es, the labeled mAb fragment retains its immunoreactivity. Biodistribution and imaging studies reveal that this conjugate is useful for the detection of hepato ma.

ACKNOWLEGDGMENTS The authors are grateful to Dr. Wang Jing for mice imaging and the Department of Nuclear Medicine of Shaanxi People’s Hospital for their support of this project.

References

1    Rhodes BA.Direct labeling of proteins with 99mTc.Nucl Med Biol,1991;18:667-676
2    Childs RL, Hnatowich DJ. Optimum condition for labeling of DTPA coupled antibodies with Technetium-99m.
      J Nucl Med, 1985;26:293-299
3    Ultee ME, Bridger GJ, Abrams MJ, Longley CB, Burton CA, Larsen SK, Henson GW, Padmanabhan S, Gaul FE, Schwartz 
      DA.Tumor imaging with technetium-99m-labeled hydrazinonicotinamide-Fab’ conjugates.J Nucl Med,1997;38:133-138
4    Joiris E, Bastin B, Thornback JR. A new method for labeling of monoclonal antibodies and their fragments with 
      technetium-99m.Nucl Med Biol,1991;18:353-356
5    Eckelman WC, Meinken G, Richards P. 99mTc-human serum albumin. J Nucl Med, 1971;12:707-710
6    John E, Thakur ML, Wilder S, Alauddin MM, Epstein AL. Technetium-99m-labeled monoclonal antibodies: influence of
      technetium-99m binding sites.J Nucl Med, 1994;35:876-881
7    Mather SJ, Ellison D. Reduction-mediated technetium-99m labeling of monoclonal antibodies.J Nucl Med, 
      1990;31:692-697
8    Rhodes BA, Zamora PO, Newell KD, Valdez EF. Technetium-99m labeling of murine monoclonal antibody fragments.
      J Nucl Med, 1986;27:685-693
9    Pauwels EKJ, Welling MM, Feitsma RIJ, Atsma DE, Nieuwenhuizen W. The labeling of proteins and LDL with 99mTc: 
      a newdirect method employing KBH4 and stannous chloride. Nucl Med Biol, 1993;20:825-833
10  Schwarz SW, Connett JM, Anderson CJ, Rocque PA, Philpott GW, Guo LW, Welch MJ. Evaluation of a direct method for
      technetium labeling intact and F(ab’)2 lA3, an anticolorectal monoclonal antibody.Nucl Med Biol, 1994;21:619-626
11  Qi P, Muddukrishna SN, Both RT, Rahn J, Chen A. Direct 99mTc-labeling of antibodies by sodium dithionite reduction,
      and role of ascorbate as a stabilizer in cysteine challenge. Nucl Med Biol, 1996;23:827-835
12  Hnatowich DJ, Virzi F, Fogarasi M, Rusckowski M, Winnard-JR P. Can a cysteine challenge assay predict the in vivo 
      behaviorof 99mTc-labeled antibodies. Nucl Med Biol, 1994;21:1035-1044
13  Sykes TR, Woo TK, Baum RP, Qi P, Noujaim AA. Direct labeling of monoclonal antibodies with technetium 99m by
      photoactivation.J Nucl Med, 1995;36:1913-1922
14  Nakayama M, Wada M, Araki N, Ginoza Y, Terahara T, Harada K, Sugh A, Tomiguchi S,Kojima A, Hara M, Takahashi M.
      Direct 99mTc labeling of human immunoglobulin with an insoluble macromolecular Sn () complex.
      Nucl Med Biol, 1995;22:795-802
15  Rosenzweig HS, Ranadive GN, Seskey T, Epperly MW, Bloomer WD. A novel method for the non-chromatographic 
      purificationof technetium-99m-labeled monoclonal antibodies:a study with B72.3 monoclonal antibody. Nucl Med 
      Biol,1994;21:171-178
16  Alauddin MM, Khawli LA, Epstein AL. An improved method of direct labeling monoclonal antibodies with 99mTc.
      Nucl Med Biol, 1992;19:445-454
17  Gooden CSR, Snook DE, Maraveyas A, Rowlinson BG, Peters AM, Epenetos AA. Direct technetium 99m labeling of three
      anticancer monoclonal antibodies: stability, pharmacokinetics and imaging.J Nucl Med, 1995;36:842-849
18  Chen ZN, Liu YF, Yang JZ. Anti human hepatocellular carcinoma monoclonal antibody and immunohistochemical location
      of associated antigen P60.Dankelong Kangti Tongxun, 1989;2:33-36
19  Qiu K, Chen ZN, Liu ZG, Wang Q, He FC, Qu P, Mi L, Sui YF, Liu YF. Preparation of anti hepatoma McAb HAb18 F(ab’)2
      and Fab fragments by papainic digestions in different conditions.Disi Junyi Daxue Xuebao, 1995;16:414-417
20  Ellman GL. Tissue sulphydryl groups.Arch Bioch Biophys, 1959;82:70-77
21  Thrall JH, Freitas JE, Swanson D, Rogers WL, Clare JM, Brown ML, Pitt B. Clinical comparison of cardiac blood pool
      visualization with technetium-99m red blood cells labeled in vivo and with technetium-99m human serum albumin.
      J Nucl Med, 1978;19:796-803
22  Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn-Jr PA. Determination of the immunoreactive fraction of radiolabeled
      monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.J Immun Med, 1984;72:77-89
23  Morrison RT, Lyster DM, Alcorn L, Rhodes BA, Breslow K, Burchiel SW. Radioimmunoimaging with 99mTc monoclonal
      antibodies: clinical studies. Int J Nucl Med Biol, 1984;11:184-188
24  Bian HJ, Chen ZN, Deng JL, Duan XD, Mi L, Yu XL, Xu LQ. Direct labeling of anti hepatoma monoclonal antibody fragment
      with 99mTc by an improved pretinning method. Tongweisu, 1999;12:90-94
25  Granowska M, Mather SJ, Britton KE, Bentley S, Richman P, Phillips RKS, Northover JMA. 99mTc 
      radioimmunoscintigraphyof colorectal cancer. Br J Cancer, 1990;62(Suppl ):30-33
26  Hnatowich DJ, Mardirossian G, Rusckowski M, Fogarasi M, Virzi F, Winnard-Jr P. Directly and indirectly technetium-
      99m-labeled antibodies-a comparison of in vitro and animal in vivo properties. J Nucl Med, 1993;34:109-119
27  Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ, Wolf FG, Goldenberg DM. Reduction of renal uptake 
      ofmonoclonal antibody fragments by amino acid infusion. J Nucl Med, 1996;37:829-833

Table 1

Table 1 Effect of molar ratio (Sn/GH: mAb) on quantity of-SH, fre e 99mTcO4- and colloid and labeling efficiency (%, n=3)

 

Molar ratio(Sn/GH: mAb)

SH groups/mAb

99mTcO4-

colloid

labeling efficiency

Control

0±0

62.1±4.5

1.1±1.2

2.0±0.9

101

0.43±0.04

3.0±1.4

1.4±1.1

44.6±3.8

201

1.25±0.10

2.9±1.1

1.4±0.7

72.8±5.1

301

2.46±0.08

2.0±0.9

3.2±1.4

78.6±3.2

401

3.34±0.09

1.8±1.2

2.8±1.3

84.2±2.8

501

3.61±0.12

2.1±0.8

3.6±1.5

84.4±3.4


Table 2

Table 2 Biodistribution of 99mTc-HAb 18F(ab’)2 in nude mice bearing hepatoma (x-±s, %ID/g)

 

Organ

Time after injection (h)

4

10

24

Blood

2.21±0.24

1.45±0.15

0.56±0.09

Kidney

72.38±14.37

70.47±15.23

56.45±11.36

Liver

1.82±0.48

1.59±0.31

1.43±0.27

Lung

1.62±0.34

1.40±0.17

0.75±0.21

Stomach

1.37±0.39

1.05±0.28

0.50±0.29

Spleen

2.35±0.81

2.11±0.75

1.82±0.85

Large intestine

1.16±0.34

1.42±0.39

0.94±0.32

Small intestine

0.97±0.31

0.95±0.18

0.62±0.24

Heart

2.04±0.55

1.83±0.48

1.17±0.42

Muscle

1.15±0.20

0.77±0.28

0.51±0.25

Brain

0.18±0.02

0.07±0.04

0.02±0.01

Tumor

5.14±2.26

5.84±2.98

6.57±3.01


Figures

mcith_348-01.jpg Figure 1  L-cysteine standard curve for sulphydryl d etermination using Ellman reaction.

(Click image to enlarge)

mcith_348-02.jpg Figure 2 Effect of reduction on integrity of 99mTc-labeled HAb18 F(ab’)2 as monitored by SDS-PAGE. Vertical lanes re present molar ratios of Sn/GH to HAb18 F(ab’)2: 1, 101; 2, 201; 3, 30 1; 4, 401; 5, 501; 6, 601. (A)Coomassie brilliant blue R250 staining. Molecular weight (kD) is indicated at the left. (B) autoradiography.

(Click image to enlarge)

mcith_348-03.jpg Figure 3 Effect of reduction on integrity of HAb18 F(ab’)2 as monitored by SDS*PAGE. Molecular weights (kD) are indicated at the left. Vertical lanes represent molar ratios of Sn/GH to HAb18 F(ab’)2: 1, 10001; 2, 5001; 3, 501; 4, 101; 5, unreduced F(ab’)2.

(Click image to enlarge)

mcith_348-04.jpg Figure 4 Binding assay for the determination of the immunoreactive fraction of 99mTc-labeled HAb18 F(ab’)2.

(Click image to enlarge)

mcith_348-05.jpg Figure 5 Dissociation of 99mTc-labeled HAb18 F(ab’)2 with increasing molar ratio of EDTA to mAb () and L-cys to mAb ().

(Click image to enlarge)

mcith_348-06.jpg Figure 6 Images of nude mice bearing human hepatocel lular carcinoma with 99mTc-HAb18 F(ab’)2 at 24h.

(Click image to enlarge)

 


http://www.biology-online.org/articles/direct-technetium-99m-labeling-anti-hepatoma.html